Home › Hallucinations › NCT04366518
Toward a Computationally-Informed, Personalized Treatment for Hallucinations
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 18-65 * English speaking * Right handedness * Diagnosed with schizophrenia schizoaffective, schizophreniform, schizotypal, or brief psychotic disorder * History of auditory verbal hallucinations occurring at least weekly Exclusion Criteria: * Current substance dependence or active use as determined by drug test. * Any neurological, medical or developmental problem that is known to impair cognition significantly * Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia * History of seizures * History of violence * History of suicide * Pregnancy (determined by urine pregnancy test) * Concurrent participation in any other intervention study * History of urinary retention * History of delirium * Current use of any cholinergic or anticholinergic medication * History of asthma, diabetes, and cardiovascular disease * Evidence of cardiovascular disease on EKG * Individuals who have been on dopamine-2 antagonists for less than 6 months (to limit risk of EPS)
About the study
Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.
What is being tested
- Rivastigmine Transdermal System (drug)
- Scopolamine (drug)
- Placebo Patch (drug)
- Placebo Patch (drug)
Sponsor: Yale University · Participants: 35 · Started: Jul 15, 2021
Contact the study team
- Albert Powers, MD, PhD · Phone: 203-974-7329
Official record on ClinicalTrials.gov — NCT04366518
Locations in the U.S.
| Connecticut | Connecticut Mental Health Center, New Haven |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.